HGS's stock falls as Albuferon not superior to Pegasys in hepatitis C
This article was originally published in Scrip
Executive Summary
Human Genome Sciences' share price plummeted by 67% on Nasdaq on March 9th, closing at an all-time low of $0.55, after its lead hepatitis C candidate Albuferon (albinterferon alfa-2b) disappointed in a Phase III trial that pitted it against peginterferon alfa-2a (Roche's Pegasys), despite meeting its primary non-inferiority endpoint. HGS, however, remained optimistic about the drug's prospects and said it planned to file Albuferon worldwide in the autumn.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.